7-month, prospective, randomized, placebo-controlled double-blind trial of omalizumab in children with allergic asthma who require daily corticosteroid treatment

Trial Profile

7-month, prospective, randomized, placebo-controlled double-blind trial of omalizumab in children with allergic asthma who require daily corticosteroid treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2016 Results published in a Genentech media release.
    • 07 Jul 2016 According to a Genentech media release, t0he US FDA has approved omalizumab (Xolair) for the treatment of moderate to severe persistent asthma in children six to 11 years of age. The approval was supported from by data from this and other phase III trials.
    • 01 Mar 2016 According to a Genentech media releae, the US FDA has accepted for review the company's supplemental Biologics License Application (sBLA) to extend the indication of Xolair (omalizumab) in allergic asthma to pediatric patients. The sBLA was supported by this and other phase III trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top